A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate The Efficacy, Safety, and Pharmacokinetics of PF-06480605 in Adult Participants With Moderate To Severe Ulcerative Colitis
A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate The Efficacy, Safety, and Pharmacokinetics of PF-06480605 in Adult Participants With Moderate To Severe Ulcerative Colitis
This phase 2b study is designed to have all subjects go into a 12 week induction period to compare different doses of study drug against placebo. After induction is complete all subjects will receive active therapy for 40 weeks, followed by a 12 week follow up period.
Inclusion Criteria:
Exclusion Criteria:
New York, New York 10021, United States
New York, New York 10065, United States
New York, New York 10065, United States
New York, New York 10065, United States
Nashville, Tennessee 37212-1610, United States
Wauwatosa, Wisconsin 53226, United States
Lille, 59037, France
Rozzano, Milan 20089, Italy
Bunkyo-ku, Tokyo 113-8519, Japan
Shinjuku-ku, Tokyo 160-8582, Japan
Mérida, Yucatán 97130, Mexico
Samara, 443029, Russia
Zrenjanin, 23000, Serbia
Pathum Wan, Bangkok 10330, Thailand
Kharkiv, 61024, Ukraine
Kharkiv, 61037, Ukraine
Kyiv, 04078, Ukraine
Kyiv, 04107, Ukraine
Vinnytsia, 21009, Ukraine
Sutton Coldfield, Birmingham B74 3UP, United Kingdom